Marksans Pharma Share Price (MARKSANS)
Check the latest share price of Marksans Pharma, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Marksans Pharma Stock Performance
Get live Marksans Pharma share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹250.1Day's Price Range₹26052 Week's Low
52 Week's High
₹154.3552-Week Price Range₹358.7
| Returns % | |
| 1 Month Return | + 8.81 % |
| 3 Month Return | + 35.71 % |
| 1 Year Return | + 61.2 % |
| 3 Year Return | + 481.93 % |
| 5 Year Return | + 706.38 % |
| Market Stats | |
| Previous Close | ₹259.95 |
| Open | ₹252.00 |
| Volume | 13.56L |
| Upper Circuit | ₹311.90 |
| Lower Circuit | ₹208.00 |
Marksans Pharma Fundamentals & Key Indicators
Check Marksans Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹11,748.27 Cr
Return on Equity (ROE)
11.46
PE Ratio (TTM)
30.86
Return on capital employed (ROCE)
14.67
Industry PE ratio
57.39
Beta (LTM)
1.31
P/B Ratio
5.62
Dividend Yield
0.4
PEG Ratio
21
Quarterly Earnings Growth YOY
16.86
EPS (TTM)
6.95
Sector
Pharmaceuticals
Book Value
45.57
Technical Analysis
Bullish
View Technical Analysis
How to invest in Marksans Pharma?
Investing in Marksans Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Marksans Pharma or MARKSANS on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Marksans Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Marksans Pharma with just a few clicks!
Marksans Pharma Stock's Interest Amongst Investors
Marksans Pharma Valuation
Track how Marksans Pharma P/E has moved over time to understand its valuation trends.
Marksans Pharma in the last 5 years
Lowest (4.67x)
April 1, 2020
Today (30.86x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (46.60x)
January 24, 2018
Today’s Price to Earnings Ratio: 30.86x
Marksans Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Marksans Pharma.
based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
100% of analysts recommend a 'BUY' rating for Marksans Pharma. Average target price of ₹301
Source: S&P Global Market Intelligence
Marksans Pharma Share Price Target
Get share price movements and forecasts by analysts on Marksans Pharma.
Marksans Pharma price forecast by 3 analysts
Upside of16.10%
High
₹323
Target
₹301.00
Low
₹265
Marksans Pharma target price ₹301, a slight upside of 16.1% compared to current price of ₹259.25. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Marksans Pharma revenue growth forecast
Expected growth rate Q1, FY2027:70.96%
Forecast
Actual
Including amortisation and stock based compensations
Marksans Pharma EPS growth forecast
EPS estimate Q1, FY2027:97.98%
Forecast
Actual
Source: S&P Global Market Intelligence
Marksans Pharma Financial Results
Get the annual and quarterly financial summary of Marksans Pharma, including revenue, profit, loss and more.
Indices Featuring Marksans Pharma Stock
Check stock indices that include Marksans Pharma.
Marksans Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Marksans Pharma.
Marksans Pharma Ltd Earnings Results
Marksans Pharma Ltd’s net profit jumped 15.66% since last year same period to ₹90.55Cr in the Q4 2024-2025. On a quarterly growth basis, Marksans Pharma Ltd has generated -13.4% fall in its net profits since last 3-months.
Read More about Earnings ResultsMarksans Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Marksans Pharma Ltd has declared dividend of ₹0.60 - translating a dividend yield of 0.42%.
Read More about Dividends
Marksans Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Marksans Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 43.87% | 0.00 | |
| Foreign Institutions | 11.32% | 0.00 | |
| Mutual Funds | 3.37% | 0.00 | |
| Retail Investors | 29.37% | 0.00 | |
| Others | 12.07% | 0.00 |
Marksans Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Marksans Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 11,748.27 | 141.28% | 0.51 | 314 | 2,177 | |
| NA | 6.24 | 5.19% | 5.69 | NA | NA | |
| NA | 81.58 | 58.65% | 0.51 | 1 | 40 | |
| NA | 1,949.06 | 25.81% | 0.51 | 58 | 630 | |
| NA | 69.91 | 6.88% | 0.78 | 2 | 45 |
Marksans Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Marksans Pharma.
Marksans Pharma Stake Sale and Share Surge - 11 Jun, 2025
Marksans Pharma shares surged following a block deal where OrbiMed sold a 2.27% stake. The stock rose significantly, reflecting strong market interest and positive financial performance.Marksans Pharma Secures UK Approval for Diabetes Drug - 30 May, 2025
Marksans Pharma's subsidiary, Relonchem, has received marketing authorization from the UK MHRA for Metformin Hydrochloride Oral Solution, marking a significant milestone in the anti-diabetic segment. This approval strengthens Marksans' presence in the UK market and aligns with its strategic growth vision.Brokerages Bullish on Marksans Pharma Stock - 21 May, 2025
Brokerage firms, including Choice Broking and Axis Securities, have issued BUY ratings on Marksans Pharma, citing strong growth visibility and potential upside of 15% to 33% over the next year.Marksans Pharma Reports Strong Financial Growth - 20 May, 2025
Marksans Pharma reported consolidated net sales of Rs 708.46 crore for March 2025, a 26.51% increase year-on-year. Net profit rose 15.65% to Rs 90.55 crore, while EBITDA increased by 12.75%. The EPS also improved to Rs 2.00. However, shares have seen a decline of 16.98% over the last six months.Marksans Pharma Gains Approval for Sennosides Tablets - 19 May, 2025
Marksans Pharma's subsidiary, Relonchem Limited, received marketing authorization for Sennosides 7.5 mg tablets from the UKMHRA, boosting its position in the gastrointestinal market. Shares rose over 6% following the announcement.Marksans Pharma Gains After Gabapentin Approval - 15 May, 2025
Marksans Pharma's subsidiary, Relonchem, received UKMHRA marketing authorisation for Gabapentin oral solution, leading to a 2% rise in share price on May 15, 2025.
Insights on Marksans Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 years, MARKSANS stock has moved up by 481.9%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 3.15% to 3.37% in Mar 2025 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 5 quarters, 576.54 Cr → 724.98 Cr (in ₹), with an average increase of 5.5% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 11.07% to 11.32% in Mar 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 43.87% of holdings in Mar 2025 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 29.87% to 29.37% in Mar 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 104.56 Cr → 90.55 Cr (in ₹), with an average decrease of 13.4% per quarter
About Marksans Pharma
Revenue: ₹708.46Cr as on March 2025 (Q4 FY25)
Net Profit: ₹90.73Cr as on March 2025 (Q4 FY25)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
| Organisation | Marksans Pharma Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| CEO | Mark Saldanha |
| E-voting on shares | Click here to vote |
Mutual Funds that own Marksans Pharma
Check out the Mutual Funds with significant holdings in Marksans Pharma.
FAQs
What is Marksans Pharma share price today?
Marksans Pharma share price today stands at ₹259.25, Open: ₹252, Previous Close: ₹259.95, High: ₹260, Low: ₹250.1, 52 Week High: ₹358.7, 52 Week Low: ₹154.35.
What is today's traded volume of Marksans Pharma?
Today's traded volume of Marksans Pharma is 13.56L. Which means that 13.56L shares of Marksans Pharma were bought and sold on the stock market during today's trading session.
What is Marksans Pharma's market cap today?
Today's market capitalisation of Marksans Pharma is ₹11,748.27 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Marksans Pharma?
Marksans Pharma’s 52 week high is ₹358.7 and 52 week low is ₹154.35. The current share price of Marksans Pharma is ₹259.25, which is -27.73% down from its 52 week high and 67.96% up from its 52 week low.